Oct 13, 2016 7:00am EDT Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH
Sep 20, 2016 7:00am EDT Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal
Sep 13, 2016 7:00am EDT Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial
Sep 07, 2016 7:00am EDT Can-Fite to Present at Rodman & Renshaw Conference in New York City on September 12, 2016
Aug 08, 2016 7:00am EDT Can-Fite's Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology
Jul 25, 2016 7:00am EDT Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD
Jun 15, 2016 7:00am EDT Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects
Jun 07, 2016 7:00am EDT Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101)